{"filing":{"accession_number":"0001104659-26-078847","cik":"0001701541","ticker":"BDTX","company_name":"Black Diamond Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"tm2619324d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465926078847/tm2619324d1_8k.htm"},"events":[{"id":14654,"run_id":13056,"accession_number":"0001104659-26-078847","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from Black Diamond Therapeutics' 2026 Annual Meeting held on June 26, 2026, filed under Item 5.07. The filing reports final voting tallies for four proposals: election of two Class III directors (Shannon Campbell and Kapil Dhingra), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, and determination of voting frequency for future compensation advisory votes. The disclosure includes vote counts (FOR, AGAINST, ABSTAIN, BROKER NON-VOTES) for each proposal, making this a textbook shareholder_vote_results event.","company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12147,"accession_number":"0001104659-26-078847","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Black Diamond Therapeutics' 2026 Annual Meeting held on June 26, 2026, filed under Item 5.07. The filing reports final voting tallies for four proposals: election of two Class III directors (Shannon Campbell and Kapil Dhingra), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, and determination of voting frequency for future compensation advisory votes. The disclosure includes vote counts (FOR, AGAINST, ABSTAIN, BROKER NON-VOTES) for each proposal, making this a textbook shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:22:08.883182+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12147,"accession_number":"0001104659-26-078847","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Black Diamond Therapeutics' 2026 Annual Meeting held on June 26, 2026, filed under Item 5.07. The filing reports final voting tallies for four proposals: election of two Class III directors (Shannon Campbell and Kapil Dhingra), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, and determination of voting frequency for future compensation advisory votes. The disclosure includes vote counts (FOR, AGAINST, ABSTAIN, BROKER NON-VOTES) for each proposal, making this a textbook shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:22:08.883182+00:00","company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","filing_date":"2026-06-29"}]}